The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus

Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus

February 18, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

HCQ Non-Adherence Rampant

Dr. Petri began by reviewing the short- and long-term benefits of HCQ, which extend beyond its benefits for disease activity. She argued that, instead of being worried patients are being prescribed too much HCQ, clinicians should worry about patients who take too little. She worries that when ophthalmologists warn patients they may go blind from HCQ therapy, they contribute to the problem of compliance. The problem with HCQ adherence was underscored by a study that revealed that approximately half the patients with SLE were non-adherent.6 Moreover, 29% of adolescents and young adults with SLE had undetectable levels of HCQ in their blood and these levels correlated with refill rates.

You Might Also Like
  • HCQ Debate: Should Dose Be No More Than 5 mg/kg in All SLE Patients?
  • Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App
  • Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine
Explore This Issue
February 2019
Also By This Author
  • Depression in Ankylosing Spondylitis: Mastery Is Key

In reviewing the 2016 AAO guidelines, Dr. Petri noted two quotes from the guidelines: 1) “Patients … should be informed about … proper dose levels”; and 2) “It is not clear that there is any truly ‘safe’ dosage for long durations of use.” Dr. Petri pointed out that once patients have been given this HCQ talk by their ophthalmologist, she often cannot get them to adhere to HCQ doses she prescribes.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

These guidelines also make it difficult for her to have a conversation with her patients about why they may need a higher dose. “I worry that this whole discussion has been covered by fear. Fear of blindness,” she emphasized, adding, “There is no reason to make our patients so afraid of a very important drug.”

She concluded by explaining her defense of HCQ stems from the fact that she is protective of her patients. “HCQ is the most important medication we have for lupus. It is the only medication that improves survival,” she stated.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In Dr. Rosenbaum’s rebuttal, he agreed with Dr. Petri’s final thoughts, concluding, “I think we agree on much more than we disagree about. I prescribe HCQ for every patient I have with RA and every patient I have with lupus. Every medication decision [involves a risk-to-benefit discussion].”

Both Dr. Rosenbaum and Dr. Petri encouraged rheumatologists and ophthalmologists to come together to revise the guidelines to reflect that HCQ is a critical medication for this patient population and that the prescription of HCQ is as much art as science.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019 Jan;96:1–13.
  2. Saxena A, Izmirly PM, Mendez B, et al. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev. 2014 Nov–Dec;22(6):263–267.
  3. Cabral RTS, Klumb EM, Couto MINN, Carneiro S. Evaluation of toxicretinopathy caused by antimalarial medications with spectral domain optical coherence tomography. Arq Bras Oftalmol. 2018 Nov 1. pii: S0004-27492018005004102.
  4. Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017 Jun;31(6):828–845.
  5. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014 Dec;132(12):1453–1460.
  6. Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in SLE: Clarifying dosing controversies and improving adherence. J Rheumatol. 2015 Nov;42(11):2092–2097.

Pages: 1 2 3 | Single Page

Filed Under: Drug Updates, Meeting Reports Tagged With: 2018 ACR/ARHP Annual Meeting, Guidelines, Hydroxychloroquine (HCQ)Issue: February 2019

You Might Also Like:
  • HCQ Debate: Should Dose Be No More Than 5 mg/kg in All SLE Patients?
  • Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App
  • Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine
  • California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.